Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Odomzo (sonidegib) for the Treatment of Locally Advanced Basal Cell Carcinoma

Drug Name (Brand / Generic)

Odomzo / sonidegib

Developed by

Novartis

Therapy Class

Anti-neoplastic agent

Product Description

Oral, selective smoothened (SMO) inhibitor

Current Indication

Locally advanced basal cell carcinoma (laBCC)

Market Sector

Oncology

Development Status

Approved in the US and Switzerland
Expand

Go Top